title: Drug-induced systemic lupus erythematosus in interferon beta-1b therapy.
abstract: Drug-induced systemic lupus erythematosus (SLE) is a rare complication of therapies with some drugs. Breaking out after months or years of therapy with a certain drug, its occurrence is likely to increase with the duration of the medication and the cumulative quantity of the drug. The symptoms of this syndrome include, in particular, arthralgia, myalgia, fever, serositis, skin exanthema and production of antinuclear (ANA) antibodies. In contrast to SLE, its symptoms gradually abate after discontinuation of the inducing agent. The authors describe the case of a 43-year-old patient suffering from multiple sclerosis who experienced drug-induced SLE after 8-year application of interferon (IFN) beta-1b.
authors.affiliation: Department of Neurology, Palacky University Medical School, University Hospital, Olomouc, Czech Republic. sladkovav@centrum.cz
authors.forename: Vladimira
authors.initials: V
authors.lastname: Sladkova
authors.forename: Jan
authors.initials: J
authors.lastname: Mares
authors.forename: Blanka
authors.initials: B
authors.lastname: Lubenova
authors.forename: Petr
authors.initials: P
authors.lastname: Hlustik
authors.forename: Petr
authors.initials: P
authors.lastname: Kanovsky
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta